Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altimmune, Inc. (NASDAQ:ALT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Rich Eisenstadt - Chief Financial Officer Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Yasmeen Rahimi - Piper Sandler Corinne Jenkins - Goldman Sachs Roger Song - Jefferies Liisa Bayko - Evercore ISI Mayank Mamtani - B. Riley Jonathan Wolleben - JMP Securities Patrick Trucchio - H.C.

Altimmune, Inc. (ALT) Q1 2023 Earnings Call Transcript

Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Top-line results from the Phase 2 trial of HepTcell™  in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, May 11, 2023, at 8:30 am EDT GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2023, and provided a business update.

Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update

GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update.

Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

Axsome Therapeutics

Biogen

The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy

OmniAb Inc

Point Biopharma Global

Verrica Pharmaceuticals Inc

Adicet Bio, Inc.

AC Immune

CorMedix

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

Ardelyx

Cidara Therapeutics

FaZe Holdings Inc

ImmunityBio

Inovio Pharmaceuticals

Olaplex Holdings

RLX Technology

Silvergate Capital Corp

Tupperware

10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy Now? 10 To Watch Under $5

GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). With the achievement of this milestone, data readout is planned for the first quarter of 2024.

Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B

Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?

7 Top Penny Stocks Under $5; Time To Buy Now?

GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors.

Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

Penny stocks to buy for under $5. Are they worth it?

4 Top Penny Stocks Under $5; Time To Buy Now?

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.

Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

Analysts had lofty expectations for Altimmune and the prospects for pemvidutide in treating obesity. However, pemvidutide's side effects in a phase 2 study were concerning.

Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.

Altimmune (NASDAQ: ALT ) stock is losing value on Tuesday after the company released results from a clinical trial. That trial has to do with the company's treatment for obesity.

Why Is Altimmune (ALT) Stock Down 67% Today?

Altimmune Inc. (NASDAQ:ALT ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Vipin Garg - President, Chief Executive Officer Richard Eisenstadt - Chief Financial Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Yasmeen Rahimi - Piper Sandler Roger Song - Jefferies Corrine Jenkins - Goldman Sachs Mayank Mamtani - B. Riley Jon Wolleben - JMP Securities Joe Pantginis - HC Wainwright Operator Good day ladies and gentlemen, and welcome to the Altimmune Inc. full year and fourth quarter 2022 financial results conference call.

Altimmune (ALT) Q4 2022 Earnings Call Transcript

Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to the discontinuation of certain projects, but the company has been actively advancing other programs that are expected to deliver noteworthy revenues soon.

Altimmune's Peptide-Based Therapies Offer Substantial Opportunity

Altimmune has exposure to promising growth areas of obesity and non-alcoholic liver disease treatment. Upcoming trial data and proof of concept work for its pemvidutide compound is key to see the stock rate higher.

Altimmune: Potential Dual Action For Pemvidutide In Obesity, NASH

GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Foghorn Therapeutics

Precigen

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week

iShares Russell 2000 ETF

Marathon Digital Holdings

Proterra

Schwab U.S. Small-Cap ETF

Taseko Mines

Some of the greatest opportunities can be found in these small-cap stocks to buy. For one, a good number of small-cap stocks are severely undervalued.

7 Small-Cap Stocks with Big Growth Potential in 2023

Mr. Jordt brings over 25 years of industry experience in corporate strategy and business development Mr. Jordt brings over 25 years of industry experience in corporate strategy and business development

Altimmune Appoints Raymond Jordt as Chief Business Officer

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune's recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows:

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

Altimmune Inc (NASDAQ:ALT) and SINTX Technologies Inc (NASDAQ:SINT) are trending today.

Altimmune Stock Skyrockets on NAFLD Drug Trial Data

GAITHERSBURG, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

News for Altimmune Stock (ALT)